您当前所在的位置:首页 > 产品中心 > 产品详细信息
401900-40-1 分子结构
点击图片或这里关闭

(2S)-3-(4-acetamidophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide

ChemBase编号:72536
分子式:C19H18F3N3O6
平均质量:441.3579296
单一同位素质量:441.11476997
SMILES和InChIs

SMILES:
C(=O)([C@@](COc1ccc(cc1)NC(=O)C)(C)O)Nc1cc(c(cc1)[N+](=O)[O-])C(F)(F)F
Canonical SMILES:
CC(=O)Nc1ccc(cc1)OC[C@@](C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-])(O)C
InChI:
InChI=1S/C19H18F3N3O6/c1-11(26)23-12-3-6-14(7-4-12)31-10-18(2,28)17(27)24-13-5-8-16(25(29)30)15(9-13)19(20,21)22/h3-9,28H,10H2,1-2H3,(H,23,26)(H,24,27)/t18-/m0/s1
InChIKey:
YVXVTLGIDOACBJ-SFHVURJKSA-N

引用这个纪录

CBID:72536 http://www.chembase.cn/molecule-72536.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
(2S)-3-(4-acetamidophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
IUPAC传统名
andarine
别名
(2S)-3-[4-(Acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
N-[4-Nitro-3-(trifluoromethyl)phenyl]-(2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methylpropanamide
S 4
Andarine
CAS号
401900-40-1
PubChem SID
162037461
PubChem CID
9824562

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID
PubChem 9824562 external link

理论计算性质

理论计算性质

JChem
Acid pKa 11.77173  质子受体
质子供体 LogD (pH = 5.5) 2.7380228 
LogD (pH = 7.4) 2.7380052  Log P 2.738023 
摩尔折射率 105.7954 cm3 极化性 37.89809 Å3
极化表面积 133.48 Å2 可自由旋转的化学键
里宾斯基五规则 true 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
DMSO expand 查看数据来源
Methanol expand 查看数据来源
外观
Pale Yellow Solid expand 查看数据来源
熔点
147-149°C expand 查看数据来源
保存条件
-20°C expand 查看数据来源
Refrigerator expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
作用靶点
Androgen Receptor expand 查看数据来源
成盐信息
Free Base expand 查看数据来源
质检报告
下载链接 expand 查看数据来源

详细说明

详细说明

Selleck Chemicals Selleck Chemicals TRC TRC
Selleck Chemicals -  S1140 external link
Research Area
Description Cancer
Biological Activity
Description Andarine (GTX-007) is a selective nonsteroidal androgen receptor (AR) agonist with Ki of 4 nM.
Targets AR
IC50 4 nM (Ki) [1]
In Vitro Andarine stimulates AR-mediated transcription to 93% of that observed for 1 nM DHT at a concentration of 10 nM. [1]
In Vivo Andarine exhibits potent and efficacious anabolic activity and results in dose-dependent stimulation of growth in prostate, seminal vesicles, and levator ani muscle with the ED50 of 0.43 mg/day, 0.55 mg/day, and 0.14 mg/day, respectively. Besides, Andarine shows no dose-dependent effect on castration-induced change in FSH, and partially suppresses LH production at dose rates of 0.5 mg/day or higher. [1] In dogs administrated by intravenous doses of Andarine (0.1, 1, 3, and 10 mg/kg), the total body clearance (CL) ranged from 7.4 mL/min/kg to 3.1 mL/min/kg, volume of distribution at steady state (Vss) is 1.39 L/kg and half-life of Andarine is 229 minutes, respectively. In addition, oral bioavailability is 38%, 62% and 91% for the 10 mg/kg, 1 mg/kg and 0.1 mg/kg doses, respectively. [2] Andarine demonstrates tissue-selective pharmacological activity and significantly decreased prostate weight to 79.4% at a concentration of 0.5 mg/day in intact rats. [3]
Clinical Trials
Features
Protocol
Kinase Assay [1]
In Vitro Pharmacological Activity Cytosolic AR is prepared from ventral prostates of castrated male Sprague-Dawley rats (about 250 g). The binding affinity of compounds 1, 2, 3, and 4 to the AR preparation is determined and analyzed as Mukherjee et al.in 1996. AR binding affinities of the synthesized ligands are determined by competitive binding in the presence of the high-affinity AR ligand [3H]MIB. AR binding studies are performed by incubating increasing concentrations (10?3 nM to 10,000 nM) of each ligand with cytosol and a saturating concentration of [3H]MIB (1 nM) at 4 °C for 18 hours. In preliminary experiments, the equilibrium dissociation constant (Kd) of MIB is determined under identical conditions by incubating increasing concentrations of [3H]MIB (0.01 nM to 10 nM) with cytosol. The minimum concentration of [3H]MIB required to saturate AR sites in the cytosol preparation is 1 nM. Subsequent experiments use either 1 nM or 2 nM [3H]MIB. The incubation mixtures also contains 1000 nM triamcinolone acetonide to block the interaction of MIB with progesterone receptors. For the determination of nonspecific binding, separate experiments are conducted by adding 1000 nM MIB to the incubation mixture. Separation of bound and free radioactivity at the end of incubation is achieved by the HAP method, and 0.8 mL of the ethanolic supernatant is added to 5 mL of scintillation fluid. Radioactivity is counted in a Beckman LS 6800 liquid scintillation counter. The ability of the compounds to influence AR-mediated transcriptional activation is examined using a cotransfection system. Transcriptional activation is measured using a single concentration (10 nM) of the indicated compound and reported as a percentage of the transcriptional activation observed for 1 nM DHT.
Animal Study [1]
Animal Models Male Sprague-Dawley rats and castrated rat model.
Formulation Andarine is dissolved in minimal amounts of ethanol and then diluted to final concentrations with PEG 300.
Doses ≤1 mg/day
Administration Administered via osmotic pump.
References
[1] Yin D, et al. J Pharmacol Exp Ther. 2003, 304(3), 1334-1340.
[2] Perera MA, et al. PharmSci. 2002, 4(4).
[3] Gao W, et al. Endocrinology. 2004, 145(12), 5420-5428.
Toronto Research Chemicals -  A637470 external link
It is a potent and tissue-selective androgen receptor modulator (SARM) used as antiosteoporotic agent.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle